NeuroScientific Biopharmaceuticals (NSB) Investor Presentation summary

Business overview and leadership

• Focuses on developing patented mesenchymal stem cell (MSC) solutions for complex autoimmune and inflammatory disorders, leveraging a strong leadership team with deep experience in biotech, finance, and clinical development.

• Holds a market capitalization of approximately $60 million and $7.3 million in cash as of August 2025.

• Specializes in the StemSmart™ technology platform, a patented method for manufacturing MSCs with global IP protection.

Technology and clinical efficacy

• StemSmart™ MSCs are engineered for increased potency, safety, and efficacy, showing a 78% overall response rate in refractory Crohn's Phase 2 trials.

• No serious adverse events reported in multiple clinical trials and compassionate use cases.

• MSCs reduce inflammation, promote tissue repair, and modulate immune responses, making them suitable for patients unresponsive to conventional therapies.

Market opportunity and pipeline

• Addressable markets include Crohn's disease, kidney transplant rejection, lung disorders, and GvHD, with global markets projected to grow significantly by 2030.

• Over 6 million people globally are affected by Crohn's disease, with 30% developing refractory disease or fistulas.

• Diversification into multiple indications broadens commercial potential beyond Crohn's.